Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor marrow transplantation or high-dose cytarabine intensifi-cation. Among 901 patients under age 21 years, 5-year survival w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lange, Beverly J., Smith, Franklin O., Feusner, James, Barnard, Dorothy R., Dinndorf, Patricia, Feig, Stephen, Heerema, Nyla A., Arndt, Carola, Arceci, Robert J., Seibel, Nita, Weiman, Margie, Dusenbery, Kathryn, Shannon, Kevin, Luna-Fineman, Sandra, Gerbing, Robert B., Alonzo, Todd A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2214754/
https://ncbi.nlm.nih.gov/pubmed/18000167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-04-084293
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados